JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain Cargo for Neurodegenerative Disease
By, Admin1 min read
Share
JCR Pharmaceuticals Co., Ltd. today announced that JCR has signed a Research Collaboration, Option and License Agreement with Alexion, AstraZeneca Rare Disease (
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
